摘要
目的 探讨氩氦刀冷冻治疗肝脏恶性肿瘤的临床意义。方法 2 0 0 1年 7月～ 2 0 0 2年6月 5 6例肝脏恶性肿瘤在B型超声引导下行经皮穿刺氩氦刀冷冻治疗。术后患者定期复查血清肿瘤标记物、B型超声检查及CT或MRI。结果 患者肝功能ChildA级 5 0例 ,ChildB级 5例 ,ChildC级 1例。原发性肝癌 4 6例 ,转移性肝癌 10例。小肝癌 (直径≤ 5cm)甲胎蛋白阳性者治疗后转阴占80 % ,甲胎蛋白阴性者治疗后CT或MRI复查病灶完全坏死达 6 1.5 %。转移性肝癌治疗后瘤标降至正常或CT、MRI提示病灶完全坏死者占 6 0 %。结论 氩氦刀冷冻治疗肝脏恶性肿瘤是一种微创、安全、疗效可靠的新方法。对于不适宜行手术治疗的肝脏恶性肿瘤患者是一种有效的微创外科治疗方法。
Objective To study the clinical significance of percutaneous cryocare ablation to treat liver cancer.Methods 56 patients with histologically or clinically confirmed primary or metastatic liver cancer were treated percutaneously under ultrasound guidance using cryocare surgical system between July 2001 to June 2002. All patients were followed up for serum tumor marker, CT scans, MRI images or ultra sound images. Results The therapy was performed on 56 patients including 50 cases of Child A liver reserve, 5 cases of Child B and 1 cases of Child C. There were 46 cases of primary liver cancer and 10 cases of metastasis liver cancer. In 80% patients with small liver cancer (diameter≤ 5 cm ), AFP turned to be negative after treatment. The rate of completely concreted necrosis of small hepatic malignancy whose AFP was negative shown by CT or MRI was 61.5% . The curative rate for metastasis liver cancer was 60%, which was revealed by CT, MRI or tumor marker level. Conclusion Percutaneous cryocare ablation is a novel palliative treatment for liver carcinoma. It is minimally invasive safe and effective, especially for the patients with liver cancer not suitable for surgical resection.
出处
《腹部外科》
2003年第1期16-18,共3页
Journal of Abdominal Surgery
